AR017220A1 - PHARMACEUTICAL COMPOSITION THAT INCLUDES MICELAS IN A WATER MEDIA, PROCESS FOR THE PREPARATION AND USE OF THE PHARMACEUTICAL COMPOSITION FOR THE MANUFACTURE OF A MEDICINAL PRODUCT. - Google Patents
PHARMACEUTICAL COMPOSITION THAT INCLUDES MICELAS IN A WATER MEDIA, PROCESS FOR THE PREPARATION AND USE OF THE PHARMACEUTICAL COMPOSITION FOR THE MANUFACTURE OF A MEDICINAL PRODUCT.Info
- Publication number
- AR017220A1 AR017220A1 ARP980106453A ARP980106453A AR017220A1 AR 017220 A1 AR017220 A1 AR 017220A1 AR P980106453 A ARP980106453 A AR P980106453A AR P980106453 A ARP980106453 A AR P980106453A AR 017220 A1 AR017220 A1 AR 017220A1
- Authority
- AR
- Argentina
- Prior art keywords
- pharmaceutical composition
- surfactant
- preparation
- stable
- micelas
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 5
- 238000002360 preparation method Methods 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 title abstract 2
- 238000004519 manufacturing process Methods 0.000 title 1
- 229940126601 medicinal product Drugs 0.000 title 1
- 239000000203 mixture Substances 0.000 abstract 3
- 239000004094 surface-active agent Substances 0.000 abstract 3
- 239000012736 aqueous medium Substances 0.000 abstract 2
- 239000003862 glucocorticoid Substances 0.000 abstract 2
- 239000000693 micelle Substances 0.000 abstract 2
- 208000026935 allergic disease Diseases 0.000 abstract 1
- 230000000172 allergic effect Effects 0.000 abstract 1
- 238000000354 decomposition reaction Methods 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 208000028774 intestinal disease Diseases 0.000 abstract 1
- 230000007794 irritation Effects 0.000 abstract 1
- 210000004072 lung Anatomy 0.000 abstract 1
- 239000002736 nonionic surfactant Substances 0.000 abstract 1
- 239000008180 pharmaceutical surfactant Substances 0.000 abstract 1
- 210000002345 respiratory system Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Una composicion farmacéutica que consiste en micelas en un medio acuoso, en la cual las miscelas constan de un glucocorticoesteroide lipofilo y uno ysolamente un agente tensioactivo farmacéuticamente aceptable, un procedimiento para la preparacionde una composicion farmacéutica y el empleo de lacomposicion farmacéutica para la preparacion de un medicamento para el tratamiento de enfermedades alérgicas y/o inflamatorias en el tracto respiratorio o parael tratamiento de enfermedadesintestinales. Las composiciones que contienen los glucocorticosteroides lipofilos empleados en un medio acuoso son muy difícilesde disolver en agua y luego obtener una composicion estable. Se ha descubierto que disolviendo el glucocorticosteroidelipofilo en un a gente tensioactivo,preferentemente, un agente tensioactivo no ionico, se pueden obtener composiciones estables con el glucocorticosteroide en forma micelar. El uso decomposiciones estables que comprenden por ejemplo palmitato derofleponide incorpora do en micelas formadas por un agente tensioactivo causa menos irritacion enel pulmon después de inhalacion oral por pacientes humanos, que la que se manifiesta después de la inhalacion oral del mismo agentetensioactivoindependientemente.A pharmaceutical composition consisting of micelles in an aqueous medium, in which the miscelas consist of a lipophilic glucocorticoid steroid and one and only a pharmaceutically acceptable surfactant, a process for the preparation of a pharmaceutical composition and the use of the pharmaceutical composition for the preparation of a medication for the treatment of allergic and / or inflammatory diseases in the respiratory tract or for the treatment of intestinal diseases. Compositions containing lipophilic glucocorticosteroids used in an aqueous medium are very difficult to dissolve in water and then obtain a stable composition. It has been discovered that by dissolving glucocorticosteroideliprophyl in a surfactant, preferably a non-ionic surfactant, stable compositions with the glucocorticosteroid in micellar form can be obtained. The use of stable decompositions comprising, for example, derofleponide palmitate incorporated in micelles formed by a surfactant causes less irritation in the lung after oral inhalation by human patients, than that manifested after oral inhalation of the same surfactant independently.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE9704833A SE9704833D0 (en) | 1997-12-22 | 1997-12-22 | New formulation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR017220A1 true AR017220A1 (en) | 2001-08-22 |
Family
ID=20409536
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP980106453A AR017220A1 (en) | 1997-12-22 | 1998-12-17 | PHARMACEUTICAL COMPOSITION THAT INCLUDES MICELAS IN A WATER MEDIA, PROCESS FOR THE PREPARATION AND USE OF THE PHARMACEUTICAL COMPOSITION FOR THE MANUFACTURE OF A MEDICINAL PRODUCT. |
Country Status (20)
| Country | Link |
|---|---|
| EP (1) | EP1043973A1 (en) |
| JP (1) | JP2001526210A (en) |
| KR (1) | KR20010024789A (en) |
| CN (1) | CN1283106A (en) |
| AR (1) | AR017220A1 (en) |
| AU (1) | AU1993599A (en) |
| BR (1) | BR9813811A (en) |
| CA (1) | CA2315782A1 (en) |
| EE (1) | EE200000388A (en) |
| HU (1) | HUP0102365A3 (en) |
| ID (1) | ID26945A (en) |
| IL (1) | IL136880A0 (en) |
| NO (1) | NO20003220L (en) |
| NZ (1) | NZ505073A (en) |
| PL (1) | PL341361A1 (en) |
| SE (1) | SE9704833D0 (en) |
| SK (1) | SK9532000A3 (en) |
| TR (1) | TR200001977T2 (en) |
| WO (1) | WO1999032089A1 (en) |
| ZA (1) | ZA9811461B (en) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE9902674D0 (en) * | 1999-07-12 | 1999-07-12 | Astra Ab | New composition |
| SE0000332D0 (en) * | 2000-01-31 | 2000-01-31 | Astrazeneca Ab | New use |
| US6759398B2 (en) | 2000-08-05 | 2004-07-06 | Smithkline Beecham Corporation | Anti-inflammatory androstane derivative |
| US6777399B2 (en) | 2000-08-05 | 2004-08-17 | Smithkline Beecham Corporation | Anti-inflammatory androstane derivative compositions |
| US6777400B2 (en) | 2000-08-05 | 2004-08-17 | Smithkline Beecham Corporation | Anti-inflammatory androstane derivative compositions |
| US6858593B2 (en) | 2000-08-05 | 2005-02-22 | Smithkline Beecham Corporation | Anti-inflammatory androstane derivative compositions |
| US6787532B2 (en) * | 2000-08-05 | 2004-09-07 | Smithkline Beecham Corporation | Formulation containing anti-inflammatory androstane derivatives |
| KR100889426B1 (en) | 2000-08-05 | 2009-03-23 | 글락소 그룹 리미티드 | 6.alpha., 9.alpha.-difluoro-17.alpha .- '(2-furanylcarboxyl) oxy-11.beta.-hydroxy-16.alpha.-methyl-3-oxo as anti-inflammatory -Androst-1,4-diene-17-carbothioic acid S-fluoromethyl ester |
| US6750210B2 (en) | 2000-08-05 | 2004-06-15 | Smithkline Beecham Corporation | Formulation containing novel anti-inflammatory androstane derivative |
| US6858596B2 (en) | 2000-08-05 | 2005-02-22 | Smithkline Beecham Corporation | Formulation containing anti-inflammatory androstane derivative |
| GB0019172D0 (en) | 2000-08-05 | 2000-09-27 | Glaxo Group Ltd | Novel compounds |
| SE0100901D0 (en) * | 2001-03-15 | 2001-03-15 | Astrazeneca Ab | New composition |
| UA77656C2 (en) | 2001-04-07 | 2007-01-15 | Glaxo Group Ltd | S-fluoromethyl ester of 6-alpha, 9-alpha-difluoro-17-alpha-[(2-furanylcarbonyl)oxy]-11-beta-hydroxy-16- alpha-methyl-3-oxoandrosta-1,4-dien-17-beta-carbothioacid as anti-inflammatory agent |
| AU2002253342B2 (en) | 2001-04-30 | 2007-01-04 | Glaxo Group Limited | Novel anti-inflammatory androstane derivatives |
| GB2389530B (en) | 2002-06-14 | 2007-01-10 | Cipla Ltd | Pharmaceutical compositions |
| EP1661556A4 (en) * | 2003-08-20 | 2010-05-19 | Ajinomoto Kk | Medicinal preparation having improved dissolution properties |
| US8497258B2 (en) | 2005-11-12 | 2013-07-30 | The Regents Of The University Of California | Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract |
| CN100579510C (en) * | 2006-04-13 | 2010-01-13 | 新疆维吾尔自治区包虫病临床研究所 | Novel precursor micellar preparation and its production method |
| WO2009064458A2 (en) | 2007-11-13 | 2009-05-22 | Meritage Pharma, Inc. | Compositions for the treatment of inflammation of the gastrointestinal tract |
| US20090143343A1 (en) | 2007-11-13 | 2009-06-04 | Meritage Pharma, Inc. | Compositions for the treatment of inflammation of the gastrointestinal tract |
| MX2011002688A (en) * | 2008-09-12 | 2011-04-12 | Critical Pharmaceuticals Ltd | Improvements in the absorption of therapeutic agents across mucosal membranes or the skin. |
| CN101982168B (en) * | 2010-11-02 | 2012-05-23 | 山东大学 | Quercetin nano micelle preparation and preparation method thereof |
| CN102793678B (en) * | 2011-05-26 | 2017-06-30 | 邓世明 | A kind of preparation method of the Docetaxel injection without tween |
| DE102011108948A1 (en) * | 2011-07-29 | 2013-01-31 | Achim Göpferich | Aqueous, colloidal solutions of lipophilic substances, in particular drug solutions |
| JP5456802B2 (en) * | 2012-01-23 | 2014-04-02 | 株式会社Ｃａｃ | Cell migration promoter and transdermal absorbent for wound treatment |
| US10596115B2 (en) * | 2013-07-17 | 2020-03-24 | Council Of Scientific & Industrial Research | Pharmaceutical composition for the treatment of diminution of bone tissue |
| US10328087B2 (en) | 2015-07-23 | 2019-06-25 | Therapeuticsmd, Inc. | Formulations for solubilizing hormones |
| MX2018011705A (en) | 2016-04-01 | 2019-06-10 | Therapeuticsmd Inc | Steroid hormone pharmaceutical composition. |
| WO2017173044A1 (en) | 2016-04-01 | 2017-10-05 | Therapeuticsmd Inc. | Steroid hormone compositions in medium chain oils |
| KR102086316B1 (en) * | 2019-09-09 | 2020-03-09 | 한국콜마주식회사 | Cosmetic composition having excellent percutaneous absorption property |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0179583A1 (en) * | 1984-10-04 | 1986-04-30 | Merck & Co. Inc. | A system for enhancing the water dissolution rate and solubility of poorly soluble drugs |
| US4994439A (en) * | 1989-01-19 | 1991-02-19 | California Biotechnology Inc. | Transmembrane formulations for drug administration |
| SA95160463B1 (en) * | 1994-12-22 | 2005-10-04 | استرا أكتيبولاج | powders for inhalation |
-
1997
- 1997-12-22 SE SE9704833A patent/SE9704833D0/en unknown
-
1998
- 1998-12-14 ZA ZA9811461A patent/ZA9811461B/en unknown
- 1998-12-17 AR ARP980106453A patent/AR017220A1/en not_active Application Discontinuation
- 1998-12-22 AU AU19935/99A patent/AU1993599A/en not_active Abandoned
- 1998-12-22 KR KR1020007006879A patent/KR20010024789A/en not_active Withdrawn
- 1998-12-22 TR TR2000/01977T patent/TR200001977T2/en unknown
- 1998-12-22 IL IL13688098A patent/IL136880A0/en unknown
- 1998-12-22 BR BR9813811-1A patent/BR9813811A/en not_active IP Right Cessation
- 1998-12-22 ID IDW20001131A patent/ID26945A/en unknown
- 1998-12-22 WO PCT/SE1998/002426 patent/WO1999032089A1/en not_active Ceased
- 1998-12-22 SK SK953-2000A patent/SK9532000A3/en unknown
- 1998-12-22 CN CN98812507A patent/CN1283106A/en active Pending
- 1998-12-22 EE EEP200000388A patent/EE200000388A/en unknown
- 1998-12-22 HU HU0102365A patent/HUP0102365A3/en unknown
- 1998-12-22 NZ NZ505073A patent/NZ505073A/en unknown
- 1998-12-22 CA CA002315782A patent/CA2315782A1/en not_active Abandoned
- 1998-12-22 PL PL98341361A patent/PL341361A1/en unknown
- 1998-12-22 JP JP2000525082A patent/JP2001526210A/en active Pending
- 1998-12-22 EP EP98964662A patent/EP1043973A1/en not_active Withdrawn
-
2000
- 2000-06-21 NO NO20003220A patent/NO20003220L/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| PL341361A1 (en) | 2001-04-09 |
| TR200001977T2 (en) | 2000-12-21 |
| HUP0102365A2 (en) | 2001-11-28 |
| EE200000388A (en) | 2002-02-15 |
| WO1999032089A1 (en) | 1999-07-01 |
| ZA9811461B (en) | 1999-06-22 |
| HUP0102365A3 (en) | 2002-01-28 |
| SK9532000A3 (en) | 2000-11-07 |
| SE9704833D0 (en) | 1997-12-22 |
| EP1043973A1 (en) | 2000-10-18 |
| NO20003220L (en) | 2000-08-22 |
| ID26945A (en) | 2001-02-22 |
| BR9813811A (en) | 2000-10-03 |
| CN1283106A (en) | 2001-02-07 |
| IL136880A0 (en) | 2001-06-14 |
| KR20010024789A (en) | 2001-03-26 |
| CA2315782A1 (en) | 1999-07-01 |
| NZ505073A (en) | 2002-09-27 |
| AU1993599A (en) | 1999-07-12 |
| NO20003220D0 (en) | 2000-06-21 |
| JP2001526210A (en) | 2001-12-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR017220A1 (en) | PHARMACEUTICAL COMPOSITION THAT INCLUDES MICELAS IN A WATER MEDIA, PROCESS FOR THE PREPARATION AND USE OF THE PHARMACEUTICAL COMPOSITION FOR THE MANUFACTURE OF A MEDICINAL PRODUCT. | |
| Hassan et al. | Chemical permeation enhancers for transbuccal drug delivery | |
| DE69020422T3 (en) | Composition in the form of a foam containing 5-aminosalicylic acid for intra-rectal administration. | |
| ES2275948T3 (en) | A GEL THAT CONTAINS AT LEAST A RETINOID AND A PEROXIDE OF BENZOIL. | |
| KR101337578B1 (en) | Mucoadhesive xyloglucan―containing formulations useful in medical devices and in pharmaceutical formulations | |
| KR100686901B1 (en) | Pharmaceutical Compositions for Mucosal Administration | |
| JP7497980B2 (en) | Devices and methods for the treatment of body surface disorders | |
| CN1283983A (en) | Improved personal formulations | |
| US20240082332A1 (en) | Method for obtaining an extract of a plant biomass | |
| Buajeeb et al. | Efficacy of fluocinolone acetonide gel in the treatment of oral lichen planus | |
| AR012358A1 (en) | FORMULATIONS OF PROLONGED RELEASE OF ERYTHROMYCIN DERIVATIVES AND THEIR USE FOR THE MANUFACTURE OF A MEDICINAL PRODUCT | |
| CN107106512A (en) | Stop blooding and Wound protection film in oral cavity | |
| Rhodus et al. | An evaluation of a chemical cautery agent and an anti-inflammatory ointment for the treatment of recurrent aphthous stomatitis: a pilot study. | |
| Holbrook et al. | Aqueous hydrocortisone mouthwash solution: clinical evaluation | |
| ES2234681T3 (en) | PHARMACEUTICAL COMPOSITION CONTAINING CICLESONIDE FOR APPLICATION TO THE MUCOSA. | |
| CN103384513A (en) | Nasal compositions of vitamin B12 | |
| Pandey et al. | Anti-psoriatic evaluation of aloe emodin-loaded topical hydrogel in an imiquimod-induced human plaque-type psoriasis in BALB/c mice | |
| ES2738652T3 (en) | Compositions of midazolam for oral administration in the treatment of seizures to obtain rapid onset of action | |
| CN115737683A (en) | Oral spray containing exosome and preparation method thereof | |
| CN106539804A (en) | A kind of molecular traditional Chinese medicine cream for alleviating osteoarthritis pain and preparation method thereof | |
| JP4824954B2 (en) | Oral composition for the treatment of stomatitis | |
| JP2012193159A (en) | Nasal spray | |
| WO2003105821A1 (en) | A pharmaceutical composition comprising a corticosteroid and a nonsterodial anti-inflammatory agent | |
| CN104780907A (en) | Medicinal lozenge based on ibuprofen sodium dihydrate | |
| IT201900015408A1 (en) | "EYE DROPS BASED ON A STERILIZABLE LIPOSOMIAL FORMULATION BASED ON CURCUMIN AND ITS OPHTHALMIC USE" |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |